Investor directory

Neurosearch

NeuroSearch (NEUR) is a Scandinavian biopharmaceutical company listed on the Nasdaq OMX Copenhagen A/S. The core business of the company covers the development of novel pharmaceutical agents, based on a broad and well-established drug discovery platform focusing on ion channels and central nervous system (CNS) disorders. A substantial share of the activities is partner financed through strategic alliances with Eli Lilly and Company, Janssen Pharmaceutica and GlaxoSmithKline (GSK), and a license collaboration with Abbott. In addition, NeuroSearch has a broad portfolio of preclinical drug candidates and holds equity interests in several biotech companies. The company has approximately 220 employees with activities in Ballerup and Gothenburg.
http://www.neurosearch.com
http://www.ntg.dk
https://crunchbase.com/organization/neurosearch
https://pitchbook.com/profiles/company/56151-91
https://www.capitaliq.com/CIQDotNet/company.aspx?companyId=1326184

4 past transactions

The Carlson Research Group

Acquisition in 2006
The Carlson Research Group is a management consulting firm that offers recruitment and research solutions.

Atonomics

Venture Round in 2005
Atonomics is an emerging technology company that designs and manufactures the diagnostic Trace® system targeted at measuring critical biomarkers related to lifestyle diseases and chronic disease management. Trace® is positioned for screening and monitoring of disease stages in an outpatient setting including pharmacies, health kiosks, and home use. The product is designed for simplicity and ease of use while preserving quality performance and safety.

NsGene

Venture Round in 2005
NsGene is a Danish Biotech company located in the Medicon Valley region. The Company is committed to developing novel biological products for the treatment of neurological diseases and is focusing on multiple indications with high unmet needs, including Alzheimer's disease, epilepsy, neuropathic pain and Parkinson's disease.

Azign Bioscience

Acquisition in 2001
Azign Bioscience A/S develops technologies to determine gene expression, which can rationally identify genes that are affected significantly, for instance in the course of a specific disease or during treatment.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.